Video |

Working for access to long-acting cabotegravir for HIV prevention

On World AIDS Day 2022, MSF Access Campaign has released a video that sets out the benefits of a new long-acting medicine, cabotegravir (CAB-LA), to prevent HIV infection. The video highlights the access challenges around CAB-LA and what the MSF is doing with others to overcome these barriers and ensure more people can benefit from it. While MSF is planning to start using CAB-LA in a few small pilot projects, the access barriers to CAB-LA are currently likely to hinder national programmes from using it at the scale needed in-country.